The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tanadopa     [5-[2-[[(2S)-2-acetamido-4- methylsulfanyl...

Synonyms: Docarpamina, docarpamine, Docarpaminum, do Carpamine, Tanadopa (TN), ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of docarpamine


High impact information on docarpamine


Biological context of docarpamine


Anatomical context of docarpamine


Associations of docarpamine with other chemical compounds


Gene context of docarpamine

  • In conclusion, TA-870, when administered enterally to rats, produced the natriuretic effect via the DA1 dopamine receptor and positive inotropic effects via the beta 1 adrenergic receptor stimulation, and these effects were not attenuated by chronic treatment with TA-870 [15].

Analytical, diagnostic and therapeutic context of docarpamine


  1. Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. Funasaki, T., Tsutsumi, M., Takase, S., Tsuchishima, M., Ueshima, Y., Urashima, S., Shimanaka, K., Itoh, T., Kawahara, H. Am. J. Gastroenterol. (1999) [Pubmed]
  2. Cardiorenal effects of an orally active dopamine prodrug (TA-870) in patients with congestive heart failure. Kubota, J., Kubo, S., Nishimura, H., Ueyama, M., Kino, M., Nakayama, A., Hara, M., Kawamura, K. J. Cardiovasc. Pharmacol. (1989) [Pubmed]
  3. Oral administration of the dopamine prodrug docarpamine shortens need for drip infusion of dopamine in patients with low cardiac output syndrome after cardiac surgery. Matsubayashi, K., Ueda, Y., Ogino, H., Sugita, T., Sakakibara, Y., Matsuyama, K., Nomoto, T. The Thoracic and cardiovascular surgeon. (1999) [Pubmed]
  4. Effects of docarpamine on hemodynamics after open heart surgery in children. Watarida, S., Shiraishi, S., Sugita, T., Katsuyama, K., Nakajima, Y., Yamamoto, R., Yamamoto, Y., Imura, M., Hirokawa, R., Mori, A. Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia. (2000) [Pubmed]
  5. Single-nucleotide polymorphisms for diagnosis of salt-sensitive hypertension. Sanada, H., Yatabe, J., Midorikawa, S., Hashimoto, S., Watanabe, T., Moore, J.H., Ritchie, M.D., Williams, S.M., Pezzullo, J.C., Sasaki, M., Eisner, G.M., Jose, P.A., Felder, R.A. Clin. Chem. (2006) [Pubmed]
  6. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. Yoshikawa, M., Endo, H., Komatsu, K., Fujihara, M., Takaiti, O., Kagoshima, T., Umehara, M., Ishikawa, H. Drug Metab. Dispos. (1990) [Pubmed]
  7. Comparative study on the disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine hydrochloride in rats and dogs. Yoshikawa, M., Endo, H., Otsuka, M., Yamaguchi, I., Harigaya, S. Drug Metab. Dispos. (1988) [Pubmed]
  8. Effect of docarpamine, a novel orally active dopamine prodrug, on the formation of free and sulfoconjugated dopamine in patients who underwent cardiac surgery. Tano, K., Yoshizumi, M., Kitagawa, T., Hori, T., Kitaichi, T., Itoh, K., Katoh, I. Life Sci. (1997) [Pubmed]
  9. A novel orally active dopamine prodrug TA-870. III. Positive inotropic effect and cardiorenal selectivity in anesthetized dogs. Nishiyama, S., Yamaguchi, I., Akimoto, Y., Yoshikawa, M., Nakajima, H. J. Cardiovasc. Pharmacol. (1990) [Pubmed]
  10. A novel orally active dopamine prodrug TA-870. II. Evidence that TA-870 is a dopamine prodrug. Nishiyama, S., Yamaguchi, I., Akimoto, Y., Yoshikawa, M., Nakajima, H. J. Cardiovasc. Pharmacol. (1989) [Pubmed]
  11. A new method for the high performance liquid chromatographic determination of TA-870, a dopamine prodrug (catechol ester compound). Yoshikawa, M., Endo, H., Hoshino, K., Sugawara, Y., Takaiti, O., Kanda, S., Imai, K. Biomed. Chromatogr. (1990) [Pubmed]
  12. Metabolism of dopamine prodrug, docarpamine. Yoshikawa, M., Nishiyama, S., Takaiti, O. Hypertens. Res. (1995) [Pubmed]
  13. The effect of docarpamine, a dopamine pro-drug, on blood pressure and catecholamine levels in spontaneously hypertensive rats. Sanada, H., Asico, L.D., Shigetomi, S., Tanaka, K., Niimura, S., Watanabe, H., Goldstein, D.S., Felder, R.A. Clin. Exp. Hypertens. (2000) [Pubmed]
  14. Comparison of cardiorenal and emetic effects of dopamine prodrugs docarpamine (TA-870) and levodopa in dogs. Nishiyama, S., Kanno, K., Yamaguchi, I. J. Pharmacobio-dyn. (1991) [Pubmed]
  15. A novel, orally active dopamine prodrug TA-870. V. Natriuretic and positive inotropic effects in rats: an assessment after chronic administration. Nishiyama, S., Yamaguchi, I. J. Cardiovasc. Pharmacol. (1991) [Pubmed]
WikiGenes - Universities